vs
Eastern Bankshares, Inc.（EBC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Eastern Bankshares, Inc.的季度营收约是Orthofix Medical Inc.的1.3倍（$295.9M vs $219.9M），Eastern Bankshares, Inc.净利率更高（22.1% vs -1.0%，领先23.1%），Eastern Bankshares, Inc.同比增速更快（710.6% vs 2.0%），过去两年Eastern Bankshares, Inc.的营收复合增速更高（38.6% vs 8.0%）
东方银行股份有限公司总部位于美国马萨诸塞州波士顿，2020年完成股份化改制前，是美国历史最悠久、规模最大的互助银行，同时也是马萨诸塞州规模最大的社区银行，深耕本地金融服务，在区域零售及小微金融领域拥有深厚的运营积淀。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
EBC vs OFIX — 直观对比
营收规模更大
EBC
是对方的1.3倍
$219.9M
营收增速更快
EBC
高出708.6%
2.0%
净利率更高
EBC
高出23.1%
-1.0%
两年增速更快
EBC
近两年复合增速
8.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $295.9M | $219.9M |
| 净利润 | $65.3M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 22.1% | -1.0% |
| 营收同比 | 710.6% | 2.0% |
| 净利润同比 | -34.4% | 92.4% |
| 每股收益（稀释后） | $0.29 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBCOFIX
| Q1 26 | $295.9M | — | ||
| Q4 25 | $37.5M | $219.9M | ||
| Q3 25 | $241.5M | $205.6M | ||
| Q2 25 | $244.9M | $203.1M | ||
| Q1 25 | $31.1M | $193.6M | ||
| Q4 24 | $216.5M | $215.7M | ||
| Q3 24 | $203.4M | $196.6M | ||
| Q2 24 | $154.0M | $198.6M |
净利润EBCOFIX
| Q1 26 | $65.3M | — | ||
| Q4 25 | $99.5M | $-2.2M | ||
| Q3 25 | $106.1M | $-22.8M | ||
| Q2 25 | $100.2M | $-14.1M | ||
| Q1 25 | $-217.7M | $-53.1M | ||
| Q4 24 | $60.8M | $-29.1M | ||
| Q3 24 | $-6.2M | $-27.4M | ||
| Q2 24 | $26.3M | $-33.4M |
毛利率EBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率EBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | 38.9% | -8.3% | ||
| Q2 25 | 41.0% | -7.9% | ||
| Q1 25 | -590.9% | -25.2% | ||
| Q4 24 | 33.3% | -5.3% | ||
| Q3 24 | -1.6% | -9.6% | ||
| Q2 24 | 24.7% | -12.5% |
净利率EBCOFIX
| Q1 26 | 22.1% | — | ||
| Q4 25 | 265.6% | -1.0% | ||
| Q3 25 | 44.0% | -11.1% | ||
| Q2 25 | 40.9% | -6.9% | ||
| Q1 25 | -699.2% | -27.4% | ||
| Q4 24 | 28.1% | -13.5% | ||
| Q3 24 | -3.0% | -13.9% | ||
| Q2 24 | 17.1% | -16.8% |
每股收益（稀释后）EBCOFIX
| Q1 26 | $0.29 | — | ||
| Q4 25 | $0.48 | $-0.05 | ||
| Q3 25 | $0.53 | $-0.57 | ||
| Q2 25 | $0.50 | $-0.36 | ||
| Q1 25 | $-1.08 | $-1.35 | ||
| Q4 24 | $0.29 | $-0.76 | ||
| Q3 24 | $-0.03 | $-0.71 | ||
| Q2 24 | $0.16 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $551.7M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.3B | $450.0M |
| 总资产 | $30.6B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EBCOFIX
| Q1 26 | $551.7M | — | ||
| Q4 25 | $507.6M | $82.0M | ||
| Q3 25 | $703.4M | $62.9M | ||
| Q2 25 | $948.3M | $65.6M | ||
| Q1 25 | $609.0M | $58.0M | ||
| Q4 24 | $1.9B | $83.2M | ||
| Q3 24 | $1.7B | $30.1M | ||
| Q2 24 | $1.4B | $26.4M |
总债务EBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益EBCOFIX
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $450.0M | ||
| Q3 25 | $3.8B | $442.5M | ||
| Q2 25 | $3.7B | $458.3M | ||
| Q1 25 | $3.6B | $458.3M | ||
| Q4 24 | $3.6B | $503.1M | ||
| Q3 24 | $3.7B | $525.9M | ||
| Q2 24 | $3.0B | $546.0M |
总资产EBCOFIX
| Q1 26 | $30.6B | — | ||
| Q4 25 | $30.6B | $850.6M | ||
| Q3 25 | $25.5B | $832.6M | ||
| Q2 25 | $25.5B | $837.2M | ||
| Q1 25 | $25.0B | $823.1M | ||
| Q4 24 | $25.6B | $893.3M | ||
| Q3 24 | $25.5B | $867.9M | ||
| Q2 24 | $21.0B | $882.0M |
负债/权益比EBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流EBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | $432.4M | $27.7M | ||
| Q3 25 | $157.1M | $12.4M | ||
| Q2 25 | $123.9M | $11.6M | ||
| Q1 25 | $47.3M | $-18.4M | ||
| Q4 24 | $283.8M | $23.7M | ||
| Q3 24 | $108.3M | $11.7M | ||
| Q2 24 | $54.3M | $9.0M |
自由现金流EBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K |
自由现金流率EBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% |
资本支出强度EBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% |
现金转化率EBCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 4.35× | — | ||
| Q3 25 | 1.48× | — | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 4.67× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.06× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EBC
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
